Download PDF
Synlett 2003(9): 1259-1262
DOI: 10.1055/s-2003-40353
LETTER
© Georg Thieme Verlag Stuttgart ˙ New York

Improved Syntheses of the Naturally Occurring Glycosidase Inhibitor Salacinol

Ahmad Ghavamia, Kashinath S. Sadalapurea, Blair D. Johnstona, Mercedes Loberab, Barry B. Sniderb, B. Mario Pinto*a
a Department of Chemistry, Simon Fraser University, Burnaby, B.C., V5A 1S6 Canada
b Department of Chemistry, Brandeis University, MS#015, 415 South Street, Box 9110 Waltham, Massachusetts 02454-9110, USA
Fax: +1(604)2915424; e-Mail: bpinto@sfu.ca;
Further Information

Publication History

Received 9 October 2002
Publication Date:
30 June 2003 (online)

    Permissions and Reprints All articles of this category

Abstract

Improved syntheses of the naturally occurring sulfonium ion, salacinol are described. Salacinol is one of the active principles in the aqueous extracts of Salacia reticulata that are traditionally used in Sri Lanka and India for the treatment of Type 2 Diabetes. The synthetic strategy relies on the nucleophilic attack of 2,3,5-tri-O-benzyl- or 2,3,5-tri-O-p-methoxybenzyl-1,4-anhydro-4-thio-d-arabinitol at the least hindered carbon of benzylidene-protected l-erythritol-1,3-cyclic sulfate in 1,1,1,3,3,3-hexafluoro-2-propanol as solvent. The reactions are compared to those with the benzyl-protected l-erythritol-1,3-cyclic sulfate and also to those in acetone and 2-propanol. Excellent yields are obtained for the reactions with the benzylidene-protected cyclic sulfate. The synthetic route employing p-methoxybenzyl ether protecting groups is advantageous since all protecting groups in the adduct may be removed with tri­fluoroacetic acid to yield salacinol, thereby obviating the problematic deprotection of benzyl ethers by hydrogenolysis.

Key words

glycosidase inhibitors - salacinol - efficient synthesis - sulfonium salt - cyclic sulfate

    References

  • 1 Yoshikawa M. Murakami T. Shimada H. Matsuda H. Yamahara J. Tanabe G. Muraoka O. Tetrahedron Lett.  1997,  38:  8367 
    Google Scholar
  • 2 Yoshikawa M. Murakami T. Yashiro K. Matsuda H. Chem. Pharm. Bull.  1998,  46:  1339 
    CrossrefGoogle Scholar
  • 3 Yoshikawa M. Morikawa T. Matsuda H. Tanabe G. Muraoka O. Bioorg. Med. Chem.  2002,  10:  1547 
    Google Scholar
  • 4 Svansson L. Johnston BD. Gu J.-H. Patrick B. Pinto BM. J. Am. Chem. Soc.  2000,  122:  10769 
    Google Scholar
  • 5 Ghavami A. Johnston BD. Pinto BM. J. Org. Chem.  2001,  66:  2312 
    CrossrefGoogle Scholar
  • 6 Yuasa H. Takada J. Hashimoto H. Tetrahedron Lett.  2000,  41:  6615 
    Google Scholar
  • 7 Ghavami A. Johnston BD. Maddess MD. Chinapoo SM. Jensen MT. Svensson B. Pinto BM. Can. J. Chem.  2002,  80:  937 
    CrossrefGoogle Scholar
  • 8 Ghavami A. Johnston BD. Jensen MT. Svensson B. Pinto BM. J. Am. Chem. Soc.  2001,  123:  6268 
    CrossrefGoogle Scholar
  • 9 Johnston BD. Ghavami A. Jensen MT. Svensson B. Pinto BM. J. Am. Chem. Soc.  2002,  124:  8245 
    CrossrefGoogle Scholar
  • 10a Reichardt C. Solvents and Solvent Effects in Organic Chemistry   VCH; Weinheim: 1996.  2nd Ed.. p.137-147  
    Google Scholar
  • 10b Reichardt C. Solvents and Solvent Effects in Organic Chemistry   VCH; Weinheim: 1996.  2nd Ed.. p.359-384  
    Google Scholar
11

Snider, B. B.; Lobera, M. unpublished results.

12

2,3,5-Tri- O -benzyl-1,4-dideoxy-1,4-{[(2S,3S)-2,4-di-(benzyloxy)-3-sulfooxy)butyl]- episulfoniumylidene}- d -arabinitol Inner Salt ( 11). A mixture of the thioether 2 [5] (270 mg, 0.64 mmol)and 2,4-di-O-benzyl-1,3-cyclic sulfate(10) [6] [9] (280 mg, 0.77 mmol) in either acetone or HFIP (0.5 mL), containing anhydrous K2CO3 (16 mg, 0.10 mmol) was stirred in a sealed tube in an oil-bath (75-80 °C) for 14h. The solvent was removed under reduced pressure and the residue was purified by column chromatography using (CH2Cl2-MeOH, 10:1) as eluant to give the title compound 11, as an amorphous solid (29 mg, 5%) in acetone and (229 mg, 45%) in HFIP. Rf 0.40 (CH2Cl2-MeOH, 10:1); [α]D - 26 (c 1.3, CHCl3); 1H NMR (CDCl3): δ = 7.38-7.05 (25 H, m, Ar), 4.67 and 4.45 (2 H, 2d, J A,B = 11.8 Hz, CH 2Ph), 4.60 and 4.45 (2 H, 2d, J A,B = 9.5 Hz, CH 2Ph), 4.59 and 4.44 (2 H, 2d, J A,B = 11.2 Hz, CH 2Ph), 4.58 (1 H, dt, J 2 ′ ,3 ′ = 5.0 Hz, H-3′), 4.42 and 4.28 (2 H, 2d, J A,B = 11.0 Hz, CH 2Ph), 4.36 (1 H, m, H-2), 4.32 (1 H, ddd, J = 1.7, 4.1, 6.3 Hz, H-2′), 4.30 and 4.20 (2 H, 2d, J A,B = 11.7 Hz, CH 2Ph), 4.23 (1 H, m, H-3), 4.13 (1 H, dd, J 1 ′ a,1 ′ b = 13.4, J 1 ′ a,2 ′ = 2.0 Hz, H-1′a), 4.05 (1 H, d, J 2,3 = 13.3 Hz, H-1a), 4.00 (1 H, dd, J 4 ′ a,4 ′ b = 11.1, J3 ′ ,4 ′ a = 2.7 Hz, H-4′a), 3.86 (1 H, dd, J 3 ′ ,4 ′ b = 2.4, J 4 ′ a,4 ′ b = 11.3 Hz, H-4′b), 3.71 (1 H, br t, J = 9.2 Hz, H-4), 3.69 (1 H, dd, J 1 ′ b,2 ′ = 3.8, J 1 ′ b,1 ′ a = 9.2 Hz, H-1′b), 3.60 (1 H, dd, J 1a,1b = 13.5, J1b,2 = 3.8 Hz, H-1b), 3.51 (1 H, dd, J 5a,5b = 13.6, J4,5a = 9.7 Hz, H-5a), 3.49 (1 H, dd, J 4,5b = 9.7 Hz, H-5b); 13C NMR (CDCl3): δ = 137.97, 136.77, 136.71, 136.05 and 135.77 (5 ¥ Cipso Ph), 128.81-127.66 (25 C, Ph), 83.14 (C-3), 81.65 (C-2), 74.59 (C-3′), 73.81, 73.53, 3.39, 72.12, 71.84 (5 ¥ CH2Ph), 73.10 (C-2′), 68.79 (C-4′), 66.62 (C-5), 65.53 (C-4), 50.89 (C-1′), 48.07 (C-1). MALDI-TOF MS: m/z 785.41 (M+ + H), 808.32 (M+ + Na). Anal. Calcd for C44H48O9S2: C, 67.32; H, 6.16. Found: C, 67.36; H, 6.10.

13

2,3,5-Tri- O -benzyl-1,4-dideoxy-1,4-{[(2S,3S)-2,4 -benzylidenedioxy-3-(sulfooxy)butyl]-episulfonium-ylidene}- d -arabinitol Inner Salt ( 4). A mixture of the thioether 2 [5] (260 mg, 0.62 mmol)and 2,4-di-O-benzylidene-1,3-cyclic sulfate(3) [5] (200 mg, 0.74 mmol) in either acetone or HFIP (0.5 mL) containing K2CO3 (13 mg, 0.09 mmol) was treated as described above to yield the title compound 4 [5] as an amorphous solid (252 mg, 59% in acetone) and (406 mg, 94% in HFIP).

14

1,4-Anhydro-2,3,5-tri- O -( p -methoxybenzyl)-4-thio- d -arabinitol ( 12). To an ice-cold mixture of 1,4-anhydro-4-thio-d-arabinitol 7 [5] (0.98 g, 6.52 mmol)and 60% NaH (1.56 g, 39.15 mmol, 6 equiv) in THF (15 mL), a solution of p-methoxybenzyl chloride (4.59 g, 29.34 mmol, 4.5 equiv) in THF (10 mL) was added over 30 min. The reaction mixture was allowed to attain room temperature and further stirred for 1 h before heating to 55 °C for 12 h. The reaction mixture was cooled and poured in to ice-water (150 mL) and extracted with Et2O (150 mL). The organic solution was dried (Na2SO4) and concentrated. The product was purified by column chromatography [hexanes-EtOAc, 7:3] to give a colorless syrup (2.96 g, 87%). [α]D +6 (c 1, CHCl3); 1H NMR (CDCl3): δ = 7.20-6.80 (12 H, m, Ar), 4.55 (2 H, s, CH 2Ph), 4.48 and 4.45 (2 H, 2d, J A,B = 11.7 Hz, CH 2Ph), 4.42 and 4.39 (2 H, 2d, J A,B = 12.0 Hz, CH 2Ph), 4.13 (1 H, dd, J 1a,2 = 4.6, J 2,3 = 9.1 Hz, H-2), 4.05 (1 H, dd, J 2,3 = J 3,4 = 3.7 Hz, H-3), 3.81 (3 H, s, OCH 3), 3.79 (3 H, s, OCH 3), 3.76 (3 H, s, OCH 3), 3.64 (1 H, dd, J 5a,5b = 8.9, J 4,5a = 7.5 Hz, H-5a), 3.50 (1 H, ddd, J 4,5b = 6.3 Hz, H-4), 3.45 (1 H, dd, H-5b), 3.04 (1 H, dd, J 1a,1b = 11.4, J 1a,2 = 5.2 Hz, H-1a), 2.85 (1 H, dd, H-1b). 13C NMR (CDCl3): δ = 159.24, 159.16 (3 ¥ Cpara), 130.31, 130.19, 130.01 (3 Cipso), 129.48, 129.28, 129.22 (6 ¥ Cortho), 113.80, 113.74 (6 ¥ Cmeta), 84.77 (C-3), 84.70 (C-2), 72.66, 71.49, 71.20 (3 ¥ CH2Ph), 72.15 (C-5), 55.24 (3 ¥ OCH3), 48.96 (C-4), 33.07 (C-1). Anal. Calcd for C29H34O6S: C, 68.21; H, 6.71. Found: C, 67.99; H, 6.69.

15

2,3,5-Tri- O - p -Methoxybenzyl-1,4-dideoxy-1,4-{[(2 S ,3 S )-2,4-benzylidenedioxy-3-(sulfooxy)butyl]-episulfonium-ylidene}- d -arabinitol Inner Salt ( 13). A mixture of the thioether 12 (1.50 g, 2.94 mmol), and the cyclic sulfate 3 (0.96 g, 1.2 equiv) in HFIP (2.5 mL) containing anhydrous K2CO3 (30 mg) was stirred in a sealed tube in an oil-bath (55°C) overnight. TLC analysis (CH2Cl2-MeOH, 10:1) showed that the thioether 12 was completely consumed. The solvent was removed under reduced pressure and the product was purified by column chromatography (gradient of CH2Cl2 to CH2Cl2-MeOH, 10:1) to give compound 13 (2.3 g, 100%) as a colorless foam. [α]D -10.5 (c 1.1, CH2Cl2); 1H NMR (CD2Cl2): δ = 7.51-6.81 (17 H, m, Ph), 5.53 (1 H, s, C6H5CH), 4.57 (1 H, ddd, J 2 ′ ,3 ′ = J 3 ′ ,4 ′ ax = 10.0, J 3 ′ ,4 ′ eq = 5.5 Hz, H-3′), 4.49 (1 H, dd, J 4 ′ ax,4 ′ eq = 10.8 Hz, H-4′eq), 4.44 (2 H, s, CH 2Ph), 4.42-4.39 (1 H, m, H-2), 4.39 and 4.29 (2 H, 2d, J A,B = 11.4 Hz, CH 2Ph), 4.33 (1 H, dd, J 1 ′ a,1 ′ b = 13.4, J 1 ′ a,2 ′ = 2.6 Hz, H-1′a), 4.29-4.26 (1 H, m, H-3), 4.26 (1 H, ddd, H-2′), 4.19 and 4.09 (2 H, 2d, J A,B = 11.5 Hz, CH 2Ph), 4.03 (1 H, br d, J 1a,2 <1 Hz, H-1a), 3.96-3.89 (2 H, m, H-4, H-1′b), 3.80 (3 H, s, OCH3), 3.79 (3 H, s, OCH3), 3.78 (3 H, s, OCH3), 3.77 (1 H, dd, H-4′ax), 3.63 (1 H, dd, J 1a,1b = 13.3, J 1b,2 = 3.8 Hz, H-1b), 3.58 (1 H, dd, J 5a,5b = 9.9, J 4,5a = 8.5 Hz, H-5a), 3.49 (1 H, dd, J 4,5b = 7.3 Hz, H-5b); 13C NMR (CD2Cl2): δ 160.30, 160.23, 159.97, 137.20 and 130.27-126.61 (21 ¥ C, Ph), 114.45, 114.36 and 114.18 (3 ¥ C ipso , OMBn), 101.96 (PhCH), 83.29 (C-3), 82.37 (C-2), 76.76 (C-2′), 73.36, 72.43, and 72.14 (3 ¥ CH2Ph), 69.50 (C-4′), 66.71 (C-5), 66.55 (C-4), 66.45 (C-3′), 55.61 (3 C, 3 ¥ OCH3), 49.55 (C-1′), 48.48 (C-1). Anal. Calcd for C40H46O12S2: C, 61.36; H, 5.92. Found: C, 61.13; H, 6.00.

16

1,4-Dideoxy-1,4-{[(2 S ,3 S )-2,4-dihydroxy-3-(sulfooxy)butyl]-episulfoniumylidene}- d -arabinitol Inner Salt(1). Compound 13 (2.30 g, 2.94 mmol) was dissolved in trifluoroacetic acid (24 mL) and while stirring, water (2.4 mL) was added. The mixture was stirred at room temperature for 0.5 h. The solvent was removed under reduced pressure and the gummy residue was washed with CH2Cl2 (3 ¥ 20 mL). Water (15 mL) was added to dissolve the crude product, and then evaporated under reduced pressure to remove the traces of remaining acid. Salacinol (1) (0.67 g, 68%) was crystallized from MeOH. The mother liquor was concentrated and purified by column chromatography (EtOAc-MeOH-H2O, 7:3:1) to give more salacinol 1 as a white solid (0.18 g, 18%).